GLP-1s are rapidly on track to reach $100B of sales in the US by 2030, becoming a cornerstone of treatment for obesity and metabolic dysfunction. Yet, what most don’t know is that over half of GLP users cycle off the drug within one year! This might be due to cost, intolerable side effects, or simply that it doesn’t work for a particular person. As a result there is immense need for new tools to manage side effects, while helping patients maintain weight loss after coming off their GLP-1 drug.

Enter Metabolize. Based on discoveries from the lab of Dr. Jonathan Long, Stanford professor with decades of research into molecular mechanisms of energy homeostasis, Metabolize is bringing two supplements to market this summer for patients rolling off GLP-1s. Both products will be both sold as pills to consumers and can be included as an ingredient in nutritional foods. First, they have a molecule to prevent the loss of muscle mass that happens to over 60% of GLP users. Second, their hero product has been shown to induce significant weight loss in proof of concept animal models via a completely different mechanism than GLPs, with no observed safety and tolerability issues. Led by a very experienced physician entrepreneur, we think this might well be the consumer product that breaks through the noise of GLP-1 alternatives with a novel, science-backed mechanism plus the sweet safety of a supplement.